"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
Concept/Terms
Metformin- Metformin
- Dimethylguanylguanidine
- Dimethylbiguanidine
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in Harvard Catalyst Profiles by year, and whether "Metformin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 0 | 1 |
| 1993 | 1 | 0 | 1 |
| 1996 | 2 | 1 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 1 | 3 |
| 2000 | 2 | 2 | 4 |
| 2001 | 2 | 0 | 2 |
| 2002 | 3 | 1 | 4 |
| 2003 | 2 | 6 | 8 |
| 2004 | 6 | 3 | 9 |
| 2005 | 4 | 5 | 9 |
| 2006 | 1 | 6 | 7 |
| 2007 | 6 | 7 | 13 |
| 2008 | 3 | 9 | 12 |
| 2009 | 11 | 6 | 17 |
| 2010 | 7 | 7 | 14 |
| 2011 | 6 | 3 | 9 |
| 2012 | 10 | 13 | 23 |
| 2013 | 16 | 13 | 29 |
| 2014 | 24 | 11 | 35 |
| 2015 | 26 | 6 | 32 |
| 2016 | 27 | 11 | 38 |
| 2017 | 27 | 23 | 50 |
| 2018 | 16 | 16 | 32 |
| 2019 | 25 | 11 | 36 |
| 2020 | 26 | 9 | 35 |
| 2021 | 19 | 6 | 25 |
| 2022 | 2 | 0 | 2 |
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Things we do for no reason™: Routinely holding metformin in the hospital. J Hosp Med. 2022 Mar; 17(3):207-210.
-
Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes. Pharmacoepidemiol Drug Saf. 2022 May; 31(5):566-576.
-
Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care. 2021 12; 44(12):2673-2682.
-
HbA1c-Triggered Endocrinology Electronic Consultation for Type 2 Diabetes Management. J Gen Intern Med. 2022 Apr; 37(5):1081-1087.
-
Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. J Clin Endocrinol Metab. 2021 09 27; 106(10):e4179-e4191.
-
Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. Am J Respir Crit Care Med. 2021 09 15; 204(6):651-666.
-
Shape of the OGTT glucose response curve: relationship with ß-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. BMJ Open Diabetes Res Care. 2021 09; 9(1).
-
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2022 01; 111(1):218-226.
-
The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. Diabetes Obes Metab. 2021 11; 23(11):2502-2512.
-
Effects of a Behavioral Weight Loss Intervention and Metformin Treatment on Serum Urate: Results from a Randomized Clinical Trial. Nutrients. 2021 Jul 31; 13(8).